Predictive Technology Group, Inc. Announces First Members of Financial Advisory Board

Life Science Investing News

Predictive Technology Group, Inc. (OTC PINK:PRED), a life sciences technology holding Company, announces initial members of its “Financial Advisory Board.”

Predictive Technology Group, Inc. (OTC PINK:PRED), a life sciences technology holding Company, announces initial members of its “Financial Advisory Board.”
According to the press release:

The three initial Financial Advisory Board members are as follows:
Dr. Gregory A. Prince — Pioneered the prevention of respiratory syncytial virus (RSV) disease in high-risk infants through the use of monoclonal antibody (SynagisÒ is currently marketed through a partnership between MedImmune and Abbvie); DDS and PhD (pathology) at UCLA; post-doctoral fellowship at the National Institutes of Health; CEO Virion Systems; National Advisory Councils, Johns Hopkins University School of Education, Utah Valley University, Dixie State University (chair); author of over 150 scientific publications in the field of infectious diseases.
Ronald Barhorst — Retired President and CEO of ING Financial Advisers, LLC, Systematized Benefits Administrators, Inc., and ING Investment Advisors, LLC. Mr. Barhorst served as a director of ING Life Insurance Holding Company, Inc. and as an officer of several other ING companies. Mr. Barhorst currently serves as Chairman on the California State University Foundation Board of Governors.
Jonas Cedergren — Managing Director, JC Capital. He was previously Managing Director, Head of European Equity Derivatives, and Head of Northern Europe, Barclays Capital, London, Managing Director and Head of Nordics, Credit Suisse, London and Vice President, Bankers Trust. Previous Board Member of Enter Card Europe.

Bradley Robinson, President, Predictive Technology Group, Inc., stated

The commitment and wealth of experience of the members of the ‘Financial Advisory Board’ will bring valued governance and guidance. As PRED moves forward with commercialization of its diagnostics and therapeutics, in its mission of revolutionizing patient care through novel gene-base companion diagnostics and therapeutics, these ‘Financial Advisory Board’ members will provide support and advice in PRED’s current and future business direction

Click here to view the full press release. 

The Conversation (0)
×